Copper and Zinc Dysregulation in Alzheimer’s Disease

Publication date: Available online 20 October 2018Source: Trends in Pharmacological SciencesAuthor(s): Stefano L. Sensi, Alberto Granzotto, Mariacristina Siotto, Rosanna SquittiAlzheimer’s disease (AD) is one of the most common forms of dementia. Despite a wealth of knowledge on the molecular mechanisms involved in AD, current treatments have mainly focused on targeting amyloid β (Aβ) production, but have failed to show significant effects and efficacy. Therefore, a critical reconsideration of the multifactorial nature of the disease is needed. AD is a complex multifactorial disorder in which, along with Aβ and tau, the convergence of polygenic, epigenetic, environmental, vascular, and metabolic factors increases the global susceptibility to the disease and shapes its course. One of the cofactors converging on AD is the dysregulation of brain metals. In this review, we focus on the role of AD-related neurodegeneration and cognitive decline triggered by the imbalance of two endogenous metals: copper and zinc.
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research